Clinical trials
for patients

The main objective is to evaluate the efficacy of BAY 2927088 in objective response rate (ORR) assessed by blinded independent centralized review (BICR).

The main objective is to evaluate the efficacy of R-DXd treatment as measured by ORR as assessed by the investigator.

The study is being conducted to answer the following questions: What is the highest dose of ART0380 that can be administered along with a standard dose of gemcitabine to cancer patients without causing significant side effects (also known as the "recommended dose")? How often can the study products be administered to cancer patients? What are the side effects of each of the study products? What are the side effects of the combination? How do the study products affect biomarkers? Can th...

We are conducting this trial to learn more about how trastuzumab deruxtecan could provide benefits to cancer patients. The purpose of this trial is to determine the efficacy and safety of the trial drug for the treatment of a type of locally advanced solid cancer based on the level of HER2 protein expression and, in addition, to learn more about the disease being studied and the associated health problems.

The objective of this study is to determine the most appropriate dose of BI 764532 to be received in the future by patients with a cancer like yours who progressed after treatment with available standard treatments, including platinum therapy, or who are ineligible for available standard treatments. Only patients confirmed positive for a tumor marker called "DLL3" will be eligible for treatment with BI 764532 in this study.

The aim of this study is to find out the possible side effects of the study drug, whether the study drug can stop the growth or spread of cancer cells in your body, how your body processes the study drug, and how certain biomarkers or small substances in your body change in response to the study drug.

The main objective is to evaluate the safety and tolerability of multiple s.c. administrations of RAY121 in patients with complement immunodeficiencies

This study is being conducted to test whether maridebart cafraglutide [MariTide (formerly AMG 133)] is a safe drug, can reduce body weight, and can improve weight-related conditions in people like you who are living with obesity or being overweight, but do not have type 2 diabetes (T2DM, a disease that occurs when blood sugar levels are too high).

The aim of this study is to learn about the safety, tolerability and antitumor properties of NMS-01940153E administered with atezolizumab and with or without decitabine for the treatment of hepatocellular carcinoma (HCC).